This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Clinical, Biochemical, and Pharmacokinetic Study

Edouard Zarifian, MD; Bernard Scatton, PhD; Gabrio Bianchetti, PhD; Henri Cuche, MD; Henri Loo, MD; Paolo L. Morselli, MD

Arch Gen Psychiatry. 1982;39(2):212-215.

Abstract
• The effects of high doses of haloperidol on clinical status and plasma neuroleptic and prolactin concentrations and CSF levels of homovanillic acid (HVA) and β-aminobutyric acid (GABA) were investigated in three paranoid schizophrenic patients over six weeks. The patients had been receiving haloperidol. Oral dosages were increased at weekly intervals from 10 to 200 mg/day and then reduced to 10 mg/day. The increase did not affect paranoid symptoms. Neurological side effects were slightly increased in two patients and moderately reduced in one. Plasma prolactin levels, initially high, increased when the dosage was increased to 100 mg/day but did not increase further. The CSF levels of HVA and GABA increased to day 7 but returned to initial values on day 28 in two patients; they were decreased to day 28 in one patient.

Author Affiliations
From the Service Hospitalo Universitaire de Santé Mentale et de Thérapeutique, Hôpital St Anne (Drs Zarifian, Cuche, and Loo), and Synthélabo Research Department (Drs Scatton, Bianchetti, and Morselli), Paris.

Footnotes
Accepted for publication April 20, 1981.

Reprint requests to Service Hospitalo Universitaire de Santé Mentale et de Thérapeutique, Hôpital St Anne, 1 Rue Cabanis, 75014 Paris, France (Dr Zarifian).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Monoamine Neurotransmitter Interactions in Drug-Free and Neuroleptic-Treated Schizophrenics
John et al.
Arch Gen Psychiatry 1993;50:606-614.
ABSTRACT  

Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients
Browne et al.
J Psychopharmacol 1988;2:94-103.
ABSTRACT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT